Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities

12 Months Ended

Dec. 31, 2013

Supplemental Cash Flow Elements [Abstract]

Supplemental disclosure of cash flow and non-cash investing and financing activities

Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities

Selected cash payments, receipts, and noncash activities are as follows:

	Twelve Months Ended December 31,
	2013		2012		2011
Cash paid for interest	$	36,202	$	13,322	$	15,456
Income taxes paid	61,129		—		—
Purchases of equipment financed through capital leases	355,144		84,650		—
Stock issuance of 167,086 shares in lieu of Directors' fees	—		184,653		—
Deferred financing costs	27,236		20,449		—
Convertible Secured Promissory Notes issued in conjunction with the acquisition of Surgical Biologics	—		—		1,250,000
Warrants issued for placement fees associated with Senior Secured Promissory Notes	—		—		14,885
Beneficial conversion related to Note Payable with related party	—		—		80,000
Beneficial conversion related to convertible debt issued with regard to acquisition of Surgical Biologics	—		—		437,500
Beneficial conversion related to Line of Credit with related party	—		514,456		—
Stock issuance of 5,250,000 shares in conjunction with acquisition of Surgical Biologics	—		—		7,087,500
Stock issuance in connection of Earn-Out Liability of 1,174, 915 shares for 2013 and 2,632,576 shares for 2012	5,792,330		3,185,223		—
Stock issuance in exchange for convertible debt of 5,272,004 shares in 2013 and 406,664 shares in 2011	5,272,004		—		406,663
Stock issuance of 1,403,630 shares for payment of Line of Credit with related party	—		1,403,630		—
Stock issuance of 216,085 shares for exercise of cashless warrants	—		216		—
Stock issuance of 893,267 shares in payment of Convertible
Secured Promissory Notes related to acquisition of Surgical Biologics	—		893,267		2,278,052
Tenant improvement incentive	996,866		—		—
Legal fees paid for public offering	101,694		—		—
Legal fees related to public offering included in accounts payable	30,100		—		—
Legal fees related to public offering included in accrued expenses	62,396		—		—